Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 28

1.

mRNA Expression and Activity of Nucleoside Transporters in Human Hepatoma HepaRG Cells.

Mayati A, Moreau A, Jouan E, Febvre-James M, Denizot C, Parmentier Y, Fardel O.

Pharmaceutics. 2018 Nov 21;10(4). pii: E246. doi: 10.3390/pharmaceutics10040246.

2.

LC-MS/MS-based quantification of efflux transporter proteins at the BBB.

Gomez-Zepeda D, Taghi M, Smirnova M, Sergent P, Liu WQ, Chhuon C, Vidal M, Picard M, Thioulouse E, Broutin I, Guerrera IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC.

J Pharm Biomed Anal. 2019 Feb 5;164:496-508. doi: 10.1016/j.jpba.2018.11.013. Epub 2018 Nov 8.

PMID:
30453156
3.

Functional polarization of human hepatoma HepaRG cells in response to forskolin.

Mayati A, Moreau A, Le Vée M, Bruyère A, Jouan E, Denizot C, Parmentier Y, Fardel O.

Sci Rep. 2018 Oct 31;8(1):16115. doi: 10.1038/s41598-018-34421-8.

4.

Evaluation of Drug Biliary Excretion Using Sandwich-Cultured Human Hepatocytes.

Fardel O, Moreau A, Le Vée M, Denizot C, Parmentier Y.

Eur J Drug Metab Pharmacokinet. 2019 Feb;44(1):13-30. doi: 10.1007/s13318-018-0502-x. Review.

PMID:
30167999
5.

New insights in the in vitro characterisation and molecular modelling of the P-glycoprotein inhibitory promiscuity.

Bocci G, Moreau A, Vayer P, Denizot C, Fardel O, Parmentier Y.

Eur J Pharm Sci. 2018 Aug 30;121:85-94. doi: 10.1016/j.ejps.2018.04.039. Epub 2018 Apr 28.

PMID:
29709579
6.

Direct and quantitative evaluation of the major human CYP contribution (fmCYP) to drug clearance using the in vitro Silensomes™ model.

Parmentier Y, Pothier C, Hewitt N, Vincent L, Caradec F, Liu J, Lin F, Trancart MM, Guillet F, Bouaita B, Chesne C, Walther B.

Xenobiotica. 2019 Jan;49(1):22-35. doi: 10.1080/00498254.2017.1422156. Epub 2018 Jan 10.

PMID:
29297729
7.

β2-adrenergic receptor-mediated in vitro regulation of human hepatic drug transporter expression by epinephrine.

Mayati A, Moreau A, Denizot C, Stieger B, Parmentier Y, Fardel O.

Eur J Pharm Sci. 2017 Aug 30;106:302-312. doi: 10.1016/j.ejps.2017.06.010. Epub 2017 Jun 8.

PMID:
28603032
8.

Targeted unlabeled multiple reaction monitoring analysis of cell markers for the study of sample heterogeneity in isolated rat brain cortical microvessels.

Gomez-Zepeda D, Chaves C, Taghi M, Sergent P, Liu WQ, Chhuon C, Vidal M, Picard M, Thioulouse E, Broutin I, Guerrera IC, Scherrmann JM, Parmentier Y, Decleves X, Menet MC.

J Neurochem. 2017 Aug;142(4):597-609. doi: 10.1111/jnc.14095. Epub 2017 Jul 11.

9.

Prediction of renal transporter-mediated drug-drug interactions for a drug which is an OAT substrate and inhibitor using PBPK modelling.

Ball K, Jamier T, Parmentier Y, Denizot C, Mallier A, Chenel M.

Eur J Pharm Sci. 2017 Aug 30;106:122-132. doi: 10.1016/j.ejps.2017.05.055. Epub 2017 May 25.

PMID:
28552429
10.

Protein Kinases C-Mediated Regulations of Drug Transporter Activity, Localization and Expression.

Mayati A, Moreau A, Le Vée M, Stieger B, Denizot C, Parmentier Y, Fardel O.

Int J Mol Sci. 2017 Apr 4;18(4). pii: E764. doi: 10.3390/ijms18040764. Review.

11.

Effect of Gevokizumab on Interleukin-1β-Mediated Cytochrome P450 3A4 and Drug Transporter Repression in Cultured Human Hepatocytes.

Moreau A, Le Vée M, Jouan E, Denizot C, Parmentier Y, Fardel O.

Eur J Drug Metab Pharmacokinet. 2017 Oct;42(5):871-878. doi: 10.1007/s13318-017-0406-1.

PMID:
28260174
12.

Inhibition of Human Drug Transporter Activities by the Pyrethroid Pesticides Allethrin and Tetramethrin.

Chedik L, Bruyere A, Le Vee M, Stieger B, Denizot C, Parmentier Y, Potin S, Fardel O.

PLoS One. 2017 Jan 18;12(1):e0169480. doi: 10.1371/journal.pone.0169480. eCollection 2017.

13.

Drug Transporter Expression and Activity in Human Hepatoma HuH-7 Cells.

Jouan E, Le Vée M, Denizot C, Parmentier Y, Fardel O.

Pharmaceutics. 2016 Dec 28;9(1). pii: E3. doi: 10.3390/pharmaceutics9010003.

14.

Inhibition of SLC drug transporter activities by environmental bisphenols.

Bruyere A, Hubert C, Le Vee M, Chedik L, Sayyed K, Stieger B, Denizot C, Parmentier Y, Fardel O.

Toxicol In Vitro. 2017 Apr;40:34-44. doi: 10.1016/j.tiv.2016.12.009. Epub 2016 Dec 15.

PMID:
27989701
15.

Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model.

Parmentier Y, Pothier C, Delmas A, Caradec F, Trancart MM, Guillet F, Bouaita B, Chesne C, Brian Houston J, Walther B.

Xenobiotica. 2017 Jul;47(7):562-575. doi: 10.1080/00498254.2016.1208854. Epub 2016 Aug 3.

PMID:
27485383
16.

Alteration of human hepatic drug transporter activity and expression by cigarette smoke condensate.

Sayyed K, Vee ML, Abdel-Razzak Z, Jouan E, Stieger B, Denizot C, Parmentier Y, Fardel O.

Toxicology. 2016 Jul 1;363-364:58-71. doi: 10.1016/j.tox.2016.07.011. Epub 2016 Jul 19.

17.

Evaluation of P-Glycoprotein Inhibitory Potential Using a Rhodamine 123 Accumulation Assay.

Jouan E, Le Vée M, Mayati A, Denizot C, Parmentier Y, Fardel O.

Pharmaceutics. 2016 Apr 12;8(2). pii: E12. doi: 10.3390/pharmaceutics8020012.

18.

Protein Kinase C-Independent Inhibition of Organic Cation Transporter 1 Activity by the Bisindolylmaleimide Ro 31-8220.

Mayati A, Bruyere A, Moreau A, Jouan E, Denizot C, Parmentier Y, Fardel O.

PLoS One. 2015 Dec 10;10(12):e0144667. doi: 10.1371/journal.pone.0144667. eCollection 2015.

19.

Protein kinase C-dependent regulation of human hepatic drug transporter expression.

Mayati A, Le Vee M, Moreau A, Jouan E, Bucher S, Stieger B, Denizot C, Parmentier Y, Fardel O.

Biochem Pharmacol. 2015 Dec 15;98(4):703-17. doi: 10.1016/j.bcp.2015.10.007. Epub 2015 Oct 14.

20.

Analysis of Sinusoidal Drug Uptake Transporter Activities in Primary Human Hepatocytes.

Le Vée M, Jouan E, Denizot C, Parmentier Y, Fardel O.

Methods Mol Biol. 2015;1250:287-302. doi: 10.1007/978-1-4939-2074-7_21.

PMID:
26272151

Supplemental Content

Loading ...
Support Center